Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that mediates the transfer of cholesteryl esters and triglycerides between lipoproteins, primarily between HDL and LDL/VLDL. Inhibiting CETP is a therapeutic strategy aimed at raising HDL-C and lowering LDL-C to reduce the risk of cardiovascular disease. CETP is synthesized in the liver and has a boomerang-shaped structure with a central tunnel for lipid transport. Its activity influences cholesterol homeostasis and the distribution of cholesterol among lipoproteins.
CETP inhibitors reduce CETP activity, leading to increased HDL-cholesterol and decreased LDL-cholesterol levels by inhibiting the transfer of cholesteryl esters from HDL to LDL/VLDL.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholesteryl Ester Transfer Protein (CETP).